In Vitro and in Vivo Studies Reveal α-Mangostin, a Xanthonoid from Garcinia Mangostana, As a Promising Natural Antiviral Compound Against Chikungunya Virus

Overview

Journal Virol J

Publisher Biomed Central

Specialty Microbiology

Date 2021 Feb 28

PMID 33639977

Citations 18

Authors

Poonam Patil

Megha Agrawal

Shahdab Almelkar

Manish Kumar Jeengar

Ashwini More

Kalichamy Alagarasu

Naveen V Kumar

Prathama S Mainkar

Deepti Parashar

Sarah Cherian

Affiliations

Soon will be listed here.

Abstract

Background: Chikungunya virus (CHIKV), a serious health problem in several tropical countries, is the causative agent of chikungunya fever. Approved antiviral therapies or vaccines for the treatment or prevention of CHIKV infections are not available. As diverse natural phenolic compounds have been shown to possess antiviral activities, we explored the antiviral activity of α-Mangostin, a xanthanoid, against CHIKV infection.

Methods: The in vitro prophylactic and therapeutic effects of α-Mangostin on CHIKV replication in Vero E6 cells were investigated by administering it under pre, post and cotreatment conditions. The antiviral activity was determined by foci forming unit assay, quantitative RT-PCR and cell-based immune-fluorescence assay. The molecular mechanism of inhibitory action was further proposed using in silico molecular docking studies.

Results: In vitro studies revealed that 8 µM α-Mangostin completely inhibited CHIKV infectivity under the cotreatment condition. CHIKV replication was also inhibited in virus-infected mice. This is the first in vivo study which clearly showed that α-Mangostin is effective in vivo by significantly reducing virus replication in serum and muscles. Molecular docking indicated that α-Mangostin can efficiently interact with the E2-E1 heterodimeric glycoprotein and the ADP-ribose binding cavity of the nsP3 macrodomain.

Conclusions: The findings suggest that α-Mangostin can inhibit CHIKV infection and replication through possible interaction with multiple CHIKV target proteins and might act as a prophylactic/therapeutic agent against CHIKV.

Citing Articles

Applications and advancements in animal models for antiviral research on mosquito-borne arboviruses.

Tang M, Wong K, Azman A, Lani R Animal Model Exp Med. 2024; 7(5):673-684.

PMID: 38987937 PMC: 11528384. DOI: 10.1002/ame2.12471.

Explorations on the antiviral potential of zinc and magnesium salts against chikungunya virus: implications for therapeutics.

Davuluri K, Shukla S, Kakade M, Cherian S, Alagarasu K, Parashar D Front Cell Infect Microbiol. 2024; 14:1335189.

PMID: 38895735 PMC: 11183322. DOI: 10.3389/fcimb.2024.1335189.

The 8-bromobaicalein alleviated chikungunya-induced musculoskeletal inflammation and reduced the viral load in healthy adult mice.

Cao V, Loeanurit N, Hengphasatporn K, Hairani R, Wacharachaisurapol N, Prompila N Emerg Microbes Infect. 2023; 12(2):2270074.

PMID: 37842770 PMC: 10653753. DOI: 10.1080/22221751.2023.2270074.

Drug repurposing approach against chikungunya virus: an and study.

Kasabe B, Ahire G, Patil P, Punekar M, Davuluri K, Kakade M Front Cell Infect Microbiol. 2023; 13:1132538.

PMID: 37180434 PMC: 10174255. DOI: 10.3389/fcimb.2023.1132538.

Anti-Dengue Activity of Lipophilic Fraction of L. Stem.

Joshi R, Agarwal S, Patil P, Alagarasu K, Panda K, Cherian S Molecules. 2023; 28(3).

PMID: 36771120 PMC: 9921342. DOI: 10.3390/molecules28031446.

References

Mounce B, Cesaro T, Carrau L, Vallet T, Vignuzzi M . Curcumin inhibits Zika and chikungunya virus infection by inhibiting cell binding. Antiviral Res. 2017; 142:148-157. DOI: 10.1016/j.antiviral.2017.03.014. View

Parashar D, Paingankar M, Kumar S, Gokhale M, Sudeep A, Shinde S . Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in vitro and protects mice infected with the virus. PLoS Negl Trop Dis. 2013; 7(9):e2405. PMC: 3764232. DOI: 10.1371/journal.pntd.0002405. View

Choi M, Kim Y, Lee S, Chin Y, Lee C . Mangosteen xanthones suppress hepatitis C virus genome replication. Virus Genes. 2014; 49(2):208-22. DOI: 10.1007/s11262-014-1098-0. View

Chen S, Wan M, Loh B . Active constituents against HIV-1 protease from Garcinia mangostana. Planta Med. 1996; 62(4):381-2. DOI: 10.1055/s-2006-957916. View

Gao M, Nettles R, Belema M, Snyder L, Nguyen V, Fridell R . Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010; 465(7294):96-100. PMC: 7094952. DOI: 10.1038/nature08960. View

Amaral J, Taylor P, Teixeira M, Morrison T, Schoen R . The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis. Viruses. 2019; 11(3). PMC: 6466451. DOI: 10.3390/v11030289. View

Cui J, Hu W, Cai Z, Liu Y, Li S, Tao W . New medicinal properties of mangostins: analgesic activity and pharmacological characterization of active ingredients from the fruit hull of Garcinia mangostana L. Pharmacol Biochem Behav. 2010; 95(2):166-72. DOI: 10.1016/j.pbb.2009.12.021. View

Chahar H, Bharaj P, Dar L, Guleria R, Kabra S, Broor S . Co-infections with chikungunya virus and dengue virus in Delhi, India. Emerg Infect Dis. 2009; 15(7):1077-80. PMC: 2744227. DOI: 10.3201/eid1507.080638. View

Kaul T, MIDDLETON Jr E, Ogra P . Antiviral effect of flavonoids on human viruses. J Med Virol. 1985; 15(1):71-9. DOI: 10.1002/jmv.1890150110. View

10.

Suhrbier A, Linn M . Clinical and pathologic aspects of arthritis due to Ross River virus and other alphaviruses. Curr Opin Rheumatol. 2004; 16(4):374-9. DOI: 10.1097/01.bor.0000130537.76808.26. View

11.

Nguyen P, Yu H, Keller P . Identification of chikungunya virus nsP2 protease inhibitors using structure-base approaches. J Mol Graph Model. 2015; 57:1-8. DOI: 10.1016/j.jmgm.2015.01.001. View

12.

Suhrbier A . Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev Rheumatol. 2019; 15(10):597-611. DOI: 10.1038/s41584-019-0276-9. View

13.

Morrison T, Oko L, Montgomery S, Whitmore A, Lotstein A, Gunn B . A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol. 2011; 178(1):32-40. PMC: 3069999. DOI: 10.1016/j.ajpath.2010.11.018. View

14.

Zhang Y, Sun Z, Pei J, Luo Q, Zeng X, Li Q . Identification of α-Mangostin as an Agonist of Human STING. ChemMedChem. 2018; 13(19):2057-2064. DOI: 10.1002/cmdc.201800481. View

15.

Johari J, Kianmehr A, Mustafa M, AbuBakar S, Zandi K . Antiviral activity of baicalein and quercetin against the Japanese encephalitis virus. Int J Mol Sci. 2012; 13(12):16785-95. PMC: 3546721. DOI: 10.3390/ijms131216785. View

16.

Parashar D, Cherian S . Antiviral perspectives for chikungunya virus. Biomed Res Int. 2014; 2014:631642. PMC: 4052087. DOI: 10.1155/2014/631642. View

17.

Burt F, Chen W, Miner J, Lenschow D, Merits A, Schnettler E . Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017; 17(4):e107-e117. DOI: 10.1016/S1473-3099(16)30385-1. View

18.

Damle R, Jayaram N, Kulkarni S, Nigade K, Khutwad K, Gosavi S . Diagnostic potential of monoclonal antibodies against the capsid protein of chikungunya virus for detection of recent infection. Arch Virol. 2016; 161(6):1611-22. DOI: 10.1007/s00705-016-2829-4. View

19.

Chavan R, Shinde P, Girkar K, Madage R, Chowdhary A . Assessment of Anti-Influenza Activity and Hemagglutination Inhibition of Plumbago indica and Allium sativum Extracts. Pharmacognosy Res. 2016; 8(2):105-11. PMC: 4780135. DOI: 10.4103/0974-8490.172562. View

20.

Malet H, Coutard B, Jamal S, Dutartre H, Papageorgiou N, Neuvonen M . The crystal structures of Chikungunya and Venezuelan equine encephalitis virus nsP3 macro domains define a conserved adenosine binding pocket. J Virol. 2009; 83(13):6534-45. PMC: 2698539. DOI: 10.1128/JVI.00189-09. View